Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

{ "Brain Energy for Amyloid Transformation in Alzheimer's Disease Study", "This study, called BEAT-AD, is looking at how different diets affect adults with mild cognitive impairment. You would be randomly assigned to follow either a Modified Mediterranean-Ketogenic Diet (low carbohydrate/high fat) or an American Heart Association Diet (low fat/high carbohydrate) for 16 weeks. Researchers want to see if these diets change your thinking abilities, blood flow in your brain, and levels of certain proteins and hormones. The main goal is to measure a specific protein in your spinal fluid (Cerebrospinal Fluid or CSF Abeta42) after 16 weeks to see the diet's impact. The study is for people aged 55 to 85 with mild cognitive impairment and a study partner. The current status of the study is unclear.", "design": "This interventional study plans to enroll 120 participants who will be randomly assigned to one of two diet groups.", "commitments": "You would follow a specific diet for 16 weeks, with clinic visits and phone sessions occurring at baseline and throughout the 24-week study period.", "compensation": "Not stated in the trial record.", "follow_up": "There will be a follow-up assessment 8 weeks after the 16-week diet completion, making the total study duration 24 weeks.", }

Study design
Not specified.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT03472664

Brain Energy for Amyloid Transformation in Alzheimer's Disease Study

Completed
NAAges 55–85InterventionalTreatment
Wake Forest University Health Sciences
~84 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:low carbohydrate/high fat dietlow fat/high carbohydrate diet

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Cerebrospinal Fluid Abeta42
Measured over baseline
+1 more outcome measured
Alzheimer Disease
Mild Cognitive Impairment
1 sites across 1 states
North Carolina1
  • Suzanne Craft, PhD · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of amnestic mild cognitive impairment
An informant (study partner) able to provide collateral information on the participant
Stable medical condition (generally 3 months prior to screening visit) at the discretion of study physician
Stable on medications (generally 4 weeks prior to screening visit) at the discretion of study physician
Able to complete baseline assessments

Exclusion

Diagnosis of neurodegenerative illness (except for MCI);
History of a clinically significant stroke
Current evidence or history in past year of focal brain lesion, head injury with loss of consciousness or DSM-IV criteria for any major psychiatric disorder including psychosis, major depression, bipolar disorder, alcohol or substance abuse
Sensory impairment (i.e.: visual or auditory) that would preclude the participant from participating in the protocol
Diabetes that requires current use of diabetes medications
Clinically significant elevations in liver function tests
Active neoplastic disease (stable prostate cancer and non-melanoma skin cancer is permissible)
History of epilepsy or seizure within past year
Contraindications for MRI (claustrophobia, craniofacial metal implants, pacemakers)
Significant medical illness or organ failure, such as uncontrolled hypertension or cardiovascular disease, chronic obstructive pulmonary disease, liver disease, or kidney disease
  • Cerebrospinal Fluid Abeta42baseline

    Aβ42 is a a key Alzheimer's disease biomarker that reflects pathological aggregation of amyloid in the brain.

  • Cerebrospinal Fluid Abeta42week 16

    Aβ42 is a a key Alzheimer's disease biomarker that reflects pathological aggregation of amyloid in the brain.